Published in Rev Urol on January 01, 2001
Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. Prostate (2007) 1.03
Leuprorelin depot injection: patient considerations in the management of prostatic cancer. Ther Clin Risk Manag (2008) 0.80
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res (1999) 2.96
Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst (2000) 2.87
Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology (1998) 2.71
HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 2.25
Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 2.15
Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res (1998) 2.07
Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med (1998) 1.98
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1. Cancer Res (2000) 1.87
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res (2000) 1.86
Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst (1999) 1.81
Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer (2001) 1.74
Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res (2001) 1.66
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 1.54
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol (2000) 1.47
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res (2000) 1.35
Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res (1997) 1.32
Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate (2001) 1.32
Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res (2000) 1.30
Differentially expressed genes in two LNCaP prostate cancer cell lines reflecting changes during prostate cancer progression. Lab Invest (2000) 1.30
Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol (1995) 1.24
Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin Cancer Res (2001) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Target to apoptosis: a hopeful weapon for prostate cancer. Prostate (1997) 1.19
Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res (2001) 1.17
Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis (2001) 1.15
Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst (1999) 1.14
Antagonism between PTEN/MMAC1/TEP-1 and androgen receptor in growth and apoptosis of prostatic cancer cells. J Biol Chem (2001) 1.13
Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J Urol (1997) 1.13
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol (1998) 1.10
Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol Endocrinol (2000) 1.08
Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol (2001) 1.07
Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer (1999) 1.07
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer. J Biol Chem (2000) 1.07
Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res (1999) 1.05
Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res (2000) 1.04
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. Br J Cancer (1996) 1.03
Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology (1999) 1.03
Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration. Int J Cancer (1996) 1.02
Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol (2000) 1.00
Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol (1998) 0.98
Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. Hum Pathol (1998) 0.96
Early effects of castration on the vascular system of the rat ventral prostate gland. Endocrinology (1999) 0.95
Low incidence of androgen receptor gene mutations in human prostatic tumors using single strand conformation polymorphism analysis. Prostate (1996) 0.95
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer (1999) 0.94
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol (2000) 0.93
Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth Differ (2000) 0.93
CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer (1999) 0.93
Androgen receptors in prostate cancer. J Endocrinol (1996) 0.90
Increased RB1 abnormalities in human primary prostate cancer following combined androgen blockade. Prostate (1998) 0.88
A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology (1999) 0.87
Fatty acid synthase: an early molecular marker of progression of prostatic adenocarcinoma to androgen independence. J Urol (2001) 0.86
Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration. Prostate (2000) 0.84
Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem (1998) 0.84
Immunohistochemical changes in prostate cancer after androgen deprivation therapy. Mol Urol (2000) 0.83
Tyrosine kinase inhibitor as a novel signal transduction and antiproliferative agent: prostate cancer. Mol Cell Endocrinol (1996) 0.82
Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations. Am J Pathol (1999) 0.81
Anti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol (1997) 0.81
Prostate cancer: a brief history and the discovery of hormonal ablation treatment. J Urol (2001) 0.81
Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy. Cancer Surv (1991) 0.80
Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration. Prostate (1998) 0.80
Endothelin-1 in human prostatic carcinoma treated with androgen withdrawal: an immunohistochemical study. Cancer (2001) 0.79
Genes upregulated during castration-induced rat prostatic apoptosis: cloning and characterization of new cDNAs. BJU Int (2000) 0.79
Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy. Clin Cancer Res (1998) 0.78
Changing patterns of gene expression identify multiple steps during regression of rat prostate in vivo. Endocrinology (1998) 0.77
Short-term cellular effects induced by castration therapy in relation to clinical outcome in prostate cancer. Br J Cancer (1998) 0.77
Workgroup 2: human xenograft models of prostate cancer. Prostate (1998) 0.77
Alternatives to death: understanding androgen-independent prostate cancer. Nat Med (1998) 0.76
Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Br J Cancer (2001) 0.76
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat Cell Biol (2001) 2.25
Human cell hybrids: analysis of transformation and tumorigenicity. Science (1982) 2.16
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 1.68
Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol (1997) 1.59
Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab (1992) 1.53
Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ (2002) 1.48
Clonal growth of human keratinocytes with small amounts of dialyzed serum. In Vitro (1980) 1.41
Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab (1991) 1.40
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res (2001) 1.36
Growth and differentiation of human keratinocytes without a feeder layer or conditioned medium. In Vitro (1980) 1.33
SMAD3 represses androgen receptor-mediated transcription. Cancer Res (2001) 1.32
Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res (1985) 1.32
Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab (1993) 1.26
Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol (1994) 1.25
Down-regulation of a calmodulin-related gene during transformation of human mammary epithelial cells. Proc Natl Acad Sci U S A (1990) 1.19
Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res (1997) 1.19
Anchorage-independent growth of normal human fibroblasts. Proc Natl Acad Sci U S A (1981) 1.13
Preferential production of latent transforming growth factor beta-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol (2005) 1.12
Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol (1996) 1.11
Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol (1999) 1.08
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res (1990) 1.04
Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate (2006) 1.03
p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. Cancer Res (2000) 1.03
Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol (1986) 1.02
Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology (1999) 1.01
1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology (1997) 0.99
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology (1995) 0.98
Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts. Prostate (1989) 0.95
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology (2000) 0.95
Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res (1994) 0.94
Human papillomavirus detection by polymerase chain reaction in benign and malignant prostate tissue is dependent on the primer set utilized. Urology (1997) 0.92
Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res (1995) 0.92
Characterization of human keratinocyte X HeLa somatic cell hybrids. Int J Cancer (1981) 0.92
Characterization of cultured human prostatic epithelial cells by cluster designation antigen expression. Cell Tissue Res (2001) 0.91
Decreased expression of Wilms' tumor gene WT-1 and elevated expression of insulin growth factor-II (IGF-II) and type 1 IGF receptor genes in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab (1997) 0.91
Insulin-like growth factor axis abnormalities in prostatic stromal cells from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab (1994) 0.90
Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res (1989) 0.89
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer (1998) 0.89
The role of differentiation in the suppression of tumorigenicity in human cell hybrids. Int J Cancer (1982) 0.88
Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis. Oncogene (2006) 0.84
Activated Ki-ras oncogene in human prostatic adenocarcinoma. Prostate (1987) 0.84
Cytogenetic evaluation of 20 cultured primary prostatic tumors. Cancer Genet Cytogenet (1991) 0.83
Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH). Cancer Genet Cytogenet (1992) 0.83
Vitamin D and prostate cancer. Adv Exp Med Biol (1995) 0.83
Parathyroid hormone--related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells. Prostate (1996) 0.81
Acid-activated insulin-like growth factor binding protein protease activity of cathepsin D in normal and malignant prostatic epithelial cells and seminal plasma. J Cell Physiol (1997) 0.81
Re-evaluation of inhibin alpha subunit as a tumour suppressor in prostate cancer. Mol Cell Endocrinol (2004) 0.81
Transforming growth factor-beta induces growth inhibition and IGF-binding protein-3 production in prostatic stromal cells: abnormalities in cells cultured from benign prostatic hyperplasia tissues. J Endocrinol (2000) 0.80
Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone. Prostate (1986) 0.80
7S nerve growth factor is an insulin-like growth factor-binding protein protease. Endocrinology (1996) 0.80
Elevated expression of inhibin alpha in prostate cancer. J Urol (2004) 0.80
Recent advances in the development of animal and cell culture models for prostate cancer research A minireview. Urol Oncol (2011) 0.79
Brefeldin A induces p53-independent apoptosis in primary cultures of human prostatic cancer cells. J Urol (2000) 0.79
Genetic polymorphisms in the androgen receptor and type II 5 alpha-reductase genes in prostate enlargement. J Urol (2001) 0.78
Expression of prostatic factors measured by reverse transcription polymerase chain reaction in human papillomavirus type 18 deoxyribonucleic acid immortalized prostate cell lines. Urology (1998) 0.78
Role of prostatic basal cells in the regulation and suppression of human prostate cancer cells. Cancer Lett (1996) 0.77
Workgroup 2: human xenograft models of prostate cancer. Prostate (1998) 0.77
Human prostatic epithelial and stromal cell lines and strains. Urol Oncol (2011) 0.76
PR1--a monoclonal antibody that reacts with an antigen on the surface of normal and malignant prostate cells. J Natl Cancer Inst (1993) 0.76
Identification of insulin-like growth factor-binding protein-3 (IGFBP-3) fragments and IGFBP-5 proteolytic activity in human seminal plasma: a comparison of normal and vasectomized patients. J Clin Endocrinol Metab (1994) 0.76
Human papilloma virus type 18 DNA immortalized cell lines from the human prostate epithelium. Prog Clin Biol Res (1994) 0.75
Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype. Cancer Genet Cytogenet (2000) 0.75
Serial propagation of adult human prostatic epithelial cells with cholera toxin. In Vitro (1984) 0.75
Overview consensus statement. Urology (2001) 0.75
Molecular biology of proto-oncogenes in genitourinary cancers. Cancer (1987) 0.75
Prostatic expression of hensin, a protein implicated in epithelial terminal differentiation. Prostate (2001) 0.75
Oncogenes: a review with relevance to cancers of the urogenital tract. J Urol (1986) 0.75